Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12917450 | 0.95 | TOP1 (0.46) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL13744408 | 0.92 | TOP1 (0.44) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL4251735 | 0.92 | TOP1 (0.45) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL13744928 | 0.92 | TOP1 (0.45) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL12917256 | 0.89 | KDM4E (0.53) | KDM4EALDH1A1LMNAPOLBNPSR1 | |
| SCHEMBL12917322 | 0.89 | TOP1 (0.47) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL964967 | 0.89 | TOP1 (0.47) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL13744547 | 0.87 | TOP1 (0.40) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL12917377 | 0.87 | TOP1 (0.43) | TOP1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL12917364 | 0.86 | TOP1 (0.44) | TOP1KDM4EALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569563-B2 | Substituted quinolones II | AICURIS GMBH & CO. HK (DE) | 2009-08-04 | — | — | US | disclosed |
| US-7569563-B2 | Substituted quinolones II | AICURIS GMBH & CO. HK (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20080261964-A1 | Substituted quinolones II | AICURIS GMBH & CO. KG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080261964-A1 | Substituted quinolones II | AICURIS GMBH & CO. KG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261964-A1 | Substituted quinolones II | TOP2A, TPMT, TOP2B | TOP1 4/4885KDM4E 2492/4885ALDH1A1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.